Encephalomalacia Market Revenue Details, Threats in the Target Market

Posted by vinit sawant on April 2nd, 2021

Market Highlights

Cerebral softening (encephalomalacia) may be seen in a localized area of the brain depending on the cause. However, it can affect virtually any part of the brain, possibly damaging tissues of the frontal, occipital, parietal, and temporal lobe.

Increasing prevalence of neurological/brain disorder like epilepsy, rising need for better treatment, increasing investment of biotechnology and pharmaceutical industries in R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapid development of technology is likely to fuel the market growth during the forecast period. On the other hand, the higher cost of the treatment procedure may slow the market growth during the review period.

The global encephalomalacia market size is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.

Regional Analysis

The Americas dominate the global encephalomalacia market owing to the presence of huge patient population, high health care spending, and increasing government support for research & development.     

Europe holds the second largest share of the global market. The increasing focus of various government agencies on treating various brain disorders or brain injuries such as epilepsy and depression will have a positive impact on the growth of the market. The growing public awareness will boost the adoption of these devices in the European market.   

The Asia Pacific is the fastest growing encephalomalacia market across the globe. Japan holds the major share of the regional market due to the availability of technology and huge healthcare spending. Rapidly developing the economy, increasing healthcare expenditure, and government initiatives for research & development may drive the market in China and India over the assessment period.